Patent FR-2823763-A1 (FR)
Title: New polynucleotides and polypeptides of interferon alpha-6 gene comprising at least one single nucleotide polymorphism, useful for preventing or treating e.g. cancer, asthma, allergies, psoriasis, AIDS or Parkinson's disease
Inventor: ESCARY JEAN LOUIS
IPC: C12N15/21
Filed: 2001-04-18
Abstract: An isolated polynucleotide (I) comprising a 1544 base pair sequence (S1), given in the specification, provided that the nucleotide sequence comprises at least one single nucleotide polymorphism (SNP) selected from the group of a86c, c130t, c157t, a210g, t216c, t363c, c469g, t637c, t647c, c668t, a669g, c677t, a775g, c891t, or g918a, or a sequence complementary to (S1), is new.  An isolated polynucleotide (I) comprising a 1544 base pair sequence (S1), given in the specification, provided that the nucleotide sequence comprises at least one single nucleotide polymorphism (SNP) selected from the group of a86c, c130t, c157t, a210g, t216c, t363c, c469g, t637c, t647c, c668t, a669g, c677t, a775g, c891t, or g918a, or a sequence complementary to (S1), is new. The isolated polynucleotide codes for a polypeptide comprising a 189 residue amino acid sequence (S2), given in the specification, and having at least one coding SNP selected from the group of L49P, R60G, D95G, or V143M, or codes for a polypeptide comprising all or part of the sequence of S2, and having the coding SNP D95G. Independent claims are also included for the following:  (1) identifying or amplifying all or part of a polynucleotide having 80-100 % identity with S1; (2) genotyping all or part of a polynucleotide having 80-100 % identity with S1;  (3) a recombinant vector comprising (I);  (4) a host cell comprising the recombinant vector of (3); (5) separating a polypeptide; (6) a polypeptide comprising:  (a) a polypeptide encoded by (I); or (b) the sequence of S2, and having at least one coding SNP selected from the group of L49P, R60G, D95G, or V143M;  (7) a method for obtaining an immunospecific antibody; (8) an immunospecific antibody obtained from the method of (7);  (9) identifying an agent among one or more compounds to be tested which activates or inhibits the activity of the polypeptide of (6), or whose activity is potentiated or inhibited by the polypeptide of (6); (10) analyzing the biological characteristics of a subject; (11) a therapeutic agent comprising one or more compounds selected from the group of (I), the recombinant vector of (3), the host cell of (4), the polypeptide of (6), or an antibody specific for the polypeptide; (12) identifying a compound among one or more compounds to be tested having a biological activity similar to the activity of D95G mutated IFN alpha -6 gene product; (13) a compound identified by the method of (12); (14) preventing or treating in an individual a disease selected from the group of:  (a) cancers and tumors, infectious diseases, immunologically and auto-immunologically related diseases, cardiovascular diseases, metabolic diseases, central nervous system diseases, and disorders connected with chemotherapy treatments; (b) healing of wounds, anemia in dialyzed patients, and/or osteoporosis; or (c) a disorder or a disease linked to the presence of (I) in the genome of the individual; (15) increasing or decreasing the activity of the polypeptide of (6) in a subject;  (16) determining statistically relevant associations between at least one SNP selected from the group of a86c, c130t, c157t, a210g, t216c, t363c, c469g, t637c, t647c, c668t, a669g, c677t, a775g, c891t, or g918a, in the interferon (IFN) alpha -6 gene, and a disease or resistance to disease; and (17) diagnosing or determining a prognosis of a disease or a resistance to a disease.